The Retinoic Acid Derivative Ro 11-1430 in Acne vulgaris

Christiansen, Jørgen V.; Holm, Per Sonne; Reymann, Flemming

doi:10.1159/000251069

Cited by 18 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical effect of Ro 11-1430 on comedones is generally considered as lower compared to tretinoin as observed by Christiansen et al [4] and Braathen et a!. [2], A remarkable result in this study was the relative lack of a demonstrable effect on comedones even with tretinoin in a great number of the patients despite the long observation time.…”

Section: Discussionmentioning

confidence: 54%

“…However, significantly more side effects, such as erythema, desquamation and burning, occurred after treatment with tretinoin than with Ro 11-1430. In a double blind multicenter study of 257 patients with acne, Christiansen et al [4] found that tretinoin produced more frequent and more severe local side effects than Ro 11-1430, which did not produce more side effects than placebo. However, tretinoin was superior to Ro 11-1430 in reducing the number of comedones and Ro 11-1430 was significantly more effective than placebo in this respect.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ro 11–1430, a New Retinoic Acid Derivative for the Topical Treatment of Acne

Nordin¹,

Fredriksson²,

Rylander³

1981

Dermatology

View full text Add to dashboard Cite

The clinical efficacy and tolerance of a new retinoic acid derivative, Ro 11–1430, in the treatment of acne vulgaris have been compared with those of tretinoin in a double-blind trial with 60 patients during 8 weeks. The efficacy of both drugs was good. Tretinoin showed a tendency to give better effect but this was not statistically significant. However, tolerance of the new derivative was better. 48 of the patients were treated with Ro 11–1430 for another 3 months with good effect and tolerance. In a long-term study, 32 patients with previous irritation of tretinoin have been treated with Ro 11–1430 between 1.5 and 17 months with good tolerance.

show abstract

Section: Discussionmentioning

confidence: 54%

mentioning

confidence: 99%

Ro 11–1430, a New Retinoic Acid Derivative for the Topical Treatment of Acne

Nordin¹,

Fredriksson²,

Rylander³

1981

Dermatology

View full text Add to dashboard Cite

show abstract

“…It is claimed to reduce numbers of comedones , but in some studies the results are little different from placebo (NORDIN et al 1981) and there is similar disagreement about the respone of inflamed lesions (CHRISTIANSEN et al 1977;NORDIN et al 1981). Unlike isotretinoin, it appears not to be sebostatic ) and does not reduce bacterial numbers.…”

Section: Tretinoin (Retinoic Acid)mentioning

confidence: 99%

Pharmacology of the Skin II

1989

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

PrefaceThe recent interest in the pharmacology of the skin and the treatment of its diseases has come about for two reasons. The first is a realisation that many aspects of pharmacology can be studied as easily in human skin as in animal models, where they may be more relevant to human physiology and disease. Examples of this are the action of various vasoactive agents and the isolation of mediators of inflammation after UV irradiation and antigen-induced dermatitis. The second reason is the fortuitous realisation that a pharmacological approach to the treatment of skin disease need not always await the full elucidation of aetiology and mechanism. For example, whilst the argument continued unresolved as to whether the pilo-sebaceous infection which constitutes acne was due to a blocked duct or to a simple increase in sebum production, 13-cis retinoic acid, was found quite by chance totally to ablate the disease; again, whilst cyclosporin, fresh from its triumphs in organ transplantation, has been found able to suppress the rash of psoriasis, it has resuscitated the debate on aetiology.We are therefore entering a new era in which the pharmacology and clinical pharmacology of skin are being studied as a fascinating new way of exploring questions of human physiology and pharmacology as well as for the development and study of new drugs, use of which will improve disease control and at the same time help to define pathological mechanisms.It was because of this burgeoning interest in pharmacology of skin and its diseases, that this book came about. Indeed it is long overdue and was planned several years ago; we console ourselves with the thought that the delay may have served to help define certain principles which were then only just emerging.The book is divided into two volumes which are independent but complementary; the first being an account of the general pharmacology of skin, the second volume being more concerned with disease and drugs. The first volume is divided into two parts, the one dealing with the pharmacology of skin systems and their control and the other with autocoids in normal and inflamed skin. This second volume has three parts; the first part deals with the methods of measurement which are becoming of increasing importance both in studying the pharmacological effects of drugs and the clinical pharmacology of skin; the second deals with toxicology in its widest sense -including metabolism and percutaneous absorption; and the third is an account both of specific drugs and the drugs used for specific diseases.

show abstract

“…The ther apeutic effects of topically applied 0.1 % mo tretinide and 0.05% retinoic acid on acne vulgaris have been found to be similar [Christiansen et al, 1976[Christiansen et al, , 1977Braathen et al 1978], Benzoyl peroxide administered topically has been shown to have a good therapeutic effect on acne vulgaris [Liddel, 1974;Jo hansson and Sulionen, 1978], However, lo cal side-effects in the form of skin irritation were noted in 41% of the patients in the stu dy, and this effect seemed to be a toxic and not an allergic reaction.…”

Section: Introductionmentioning

confidence: 95%